Furthermore, the use of PD‐1/PD‐L1 for the treatment of NSCLC in patients who had previously received chemotherapy conferred superior OS than chemotherapy alone (HR 0.69, 95% CI 0.63–0.76). This evidence concerns the gene CD274 and non-small cell lung carcinoma.